
2026 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
Course Description
This course explores the clinical significance of germline and somatic variants in cancer and provides practical knowledge on the application of clinical guidelines and bioinformatics tools for treatment recommendations. Participants will gain an understanding of how various disciplines—medical oncology, molecular pathology, genomics, bioinformatics, and genetic counseling—collaborate in cancer care. Emphasizing the importance of multi-institutional collaboration, the course covers workflows for cancer variant interpretation, including the utilization of genomic tumor boards and variant annotation pipelines.
Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.
Webinar Series on the Fourth Tuesday of the following months
January - October from 11 am - 12 pm ET
2026 Webinar Series:
|
January 27
|
Cases in Precision Oncology Highlights from the 2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
|
|
February 24
|
TBA
|
|
March 24
|
TBA
|
|
April 28
|
TBA
|
|
May 26
|
TBA
|
|
June 23
|
TBA
|
|
July 28
|
TBA
|
|
Aug 25
|
TBA
|
|
Sept 22
|
TBA
|
|
Oct 27
|
TBA
|
Learning Objectives
At the conclusion of this series, participants should be able to:
- Apply clinical guidelines and bioinformatics tools to determine the clinical significance of germline and somatic variants in cancer
- Describe the spectrum of resources to aid in cancer variant interpretation in the clinic
- Utilize genomic tumor boards informed by multiple workflows and annotation pipelines
Registration Fees:
|
Category
|
Member Fee
|
Non-Member Fee
|
|
Professional
|
$0
|
$0
|
|
Postdoc/Trainee/Student
|
$0
|
$0
|
 |
Manuela Benary, PhD
Bioinformatician
Charité – Universitätsmedizin Berlin, Berlin, Germany
|
|
Beth Pitel, MS
Clinical Variant Scientist – Oncology
Assistant Professor of Laboratory Medicine and Pathology
Mayo Clinic
|
 |
Jason Saliba, PhD
Senior Scientist at Washington University School of Medicine in St. Louis
|
Planning Committee:Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Staff:Jane Radford, MHA, CHCP
Claudia Barnett
Accredited Continuing Education Information
Accredited Continuing Education Information:
AMA PRA Category 1 CreditTM, ASCLS P.A.C.E.®
Accreditation
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.
Claiming your Educational Credits
Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.
Learner Data Consent
ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.
Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program

All of the relevant financial relationships listed for these individuals have been mitigated.
|
Name
|
Role
|
Relationship/Company
|
|
Manuela Benary, PhD
|
Presenter, Moderator, Planner
|
Speaker: Novartis
|
|
Beth Pitel, MS
|
Presenter, Moderator, Planner
|
Somatic Advisory Board: Qiagen
|
|
Gordana Raca, MD, PhD, FACMG
|
Planner, Peer Reviewer
|
Nothing to Disclose
|
|
Jason Saliba, PhD
|
Presenter, Moderator, Planner
|
Nothing to Disclose
|
|
Jane Radford, MHA, CHCP
|
Staff
|
Nothing to Disclose
|
|
Claudia Barnett
|
Staff
|
Nothing to Disclose
|
Disclaimer
ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient